Current advances in Hodgkin’s lymphoma

Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joseph Vadakara, Benjamin Andrick
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2019
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/581c062dee694a08ac01bdf0eca28236
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:581c062dee694a08ac01bdf0eca28236
record_format	dspace
spelling	oai:doaj.org-article:581c062dee694a08ac01bdf0eca282362021-12-02T16:42:39ZCurrent advances in Hodgkin’s lymphoma2095-882X10.1016/j.cdtm.2019.02.003https://doaj.org/article/581c062dee694a08ac01bdf0eca282362019-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X18300756https://doaj.org/toc/2095-882XHodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field. Keywords: Hodgkin’s lymphoma, Brentuximab vedotin, Nivolumab, Pembrolizumab, Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)Joseph VadakaraBenjamin AndrickKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 5, Iss 1, Pp 15-24 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Joseph Vadakara Benjamin Andrick Current advances in Hodgkin’s lymphoma
description	Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field. Keywords: Hodgkin’s lymphoma, Brentuximab vedotin, Nivolumab, Pembrolizumab, Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
format	article
author	Joseph Vadakara Benjamin Andrick
author_facet	Joseph Vadakara Benjamin Andrick
author_sort	Joseph Vadakara
title	Current advances in Hodgkin’s lymphoma
title_short	Current advances in Hodgkin’s lymphoma
title_full	Current advances in Hodgkin’s lymphoma
title_fullStr	Current advances in Hodgkin’s lymphoma
title_full_unstemmed	Current advances in Hodgkin’s lymphoma
title_sort	current advances in hodgkin’s lymphoma
publisher	KeAi Communications Co., Ltd.
publishDate	2019
url	https://doaj.org/article/581c062dee694a08ac01bdf0eca28236
work_keys_str_mv	AT josephvadakara currentadvancesinhodgkinslymphoma AT benjaminandrick currentadvancesinhodgkinslymphoma
_version_	1718383516200206336

Current advances in Hodgkin’s lymphoma

Ejemplares similares